Alexander N. Shoushtari

Memorial Sloan Kettering Cancer Center — United States

Medicine · Health Sciences

53h-index22.5kcitations381works1.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(148), CAR-T cell therapy research(131), Immunotherapy and Immune Responses(107), Melanoma and MAPK Pathways(107), Ocular Oncology and Treatments(85)

Publications381 total

Table 3 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
2025Open Access
Table 2 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
2025Open Access
Supplementary Data 1 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
2025Open Access
Table 1 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
2025Open Access
Figure 2 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
2025Open Access
Figure 3 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
2025Open Access
Figure 1 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
2025Open Access
Supplementary Data 1 from Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma
2025Open Access
Supplementary Table 1 from Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma
2025Open Access
Supplementary Figures S1 to S7 from Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma
2025Open Access
Supplementary Methods 1 from Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma
2025Open Access
Clinicopathogenomic Characteristics of Primary and Metastatic Melanomas With RAF1 and BRAF Fusions
The American Journal of Surgical Pathology·2025
Bridging the Gap: Incorporating Lifileucel Into Management of Advanced PD-1 Blockade Resistant Melanomas
Journal of Clinical Oncology·2025
Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients
The Oncologist·2025· 1 citedOpen Access
Correction: Shoushtari et al. A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma. Cancers 2021, 13, 5504
Cancers·2025Open Access
Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
Clinical Cancer Research·2025Open Access
Disruption of TAD hierarchy promotes LTR co-option in cancer
Nature Genetics·2025· 3 citedOpen Access
Programmed death ligand-1 PET imaging in patients with melanoma: a pilot study
Melanoma Research·2025· 1 citedOpen Access
OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy with regulatable membrane-bound IL15 (mbIL15) in patients (pts) with immune checkpoint inhibitor (ICI)–resistant advanced melanoma: Phase 1 results of the Agni-01 multicenter study.
Journal of Clinical Oncology·2025· 3 cited
Outpatient treatment-related toxicity after hospital discharge among patients receiving lifileucel for advanced melanoma.
Journal of Clinical Oncology·2025
page 1 of 20Next →

Frequent Co-authors

Michael A. Postow(20), Richard D. Carvajal(14), Jedd D. Wolchok(12), Michael F. Berger(10), Margaret K. Callahan(10), Ahmet Zehir(9), Marc Ladanyi(9), Douglas B. Johnson(9), Paul B. Chapman(9), A. Ari Hakimi(8), David B. Solit(8), Luc G.T. Morris(8), Ryan J. Sullivan(8), Parisa Momtaz(8), Gopa Iyer(7), Charlotte E. Ariyan(7), Mrinal M. Gounder(7), Rona Yaeger(7), Ping Chi(7), Katherine S. Panageas(7)